Navigation Links
NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
Date:3/3/2008

d pressure increase. Both treated hypertensive patients and individuals with normal blood pressure appear to be affected and the dose and duration of administration also seems to be important, with hypertension occurring more frequently with chronic treatment.

NOTE 2: Ambulatory Blood Pressure Measurement (ABPM) involves using a portable device to independently measure and record blood pressure at frequent intervals over a 24-hour period with minimal disruption of a subject's daily activity. In these new studies, blood pressure measurements will be taken at 20-minute intervals between 6:00 am and 10:00 pm and every hour from 10:01 pm to 5:59 am.

NicOx (Bloomberg: COX:FP, Reuters: NCOX.PA) is a product-driven biopharmaceutical company dedicated to the development and future commercialization of investigational drugs for unmet medical needs. NicOx is applying its proprietary nitric oxide-donating technology to develop an internal portfolio of New Chemical Entities (NCEs) in the therapeutic areas of inflammatory and cardio-metabolic disease.

Resources are focused on the development of naproxcinod, a proprietary NCE and the first compound in the COX-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, which is in phase 3 clinical studies for the treatment of the signs and symptoms of osteoarthritis, with final phase 3 results anticipated in 2008.

Beyond naproxcinod, NicOx has a pipeline containing multiple nitric oxide- donating NCEs, which are in development internally and with partners, including Pfizer Inc and Merck & Co., Inc., for the treatment of prevalent and underserved diseases, such as atherosclerosis, hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).

NicOx S.A. is headquartered in France and is listed on the Euronext Paris Stock Exchange (Compartment B: Mid Caps).

This press release contains certain forward-looking statements. Although the Company believes its expectations
'/>"/>

SOURCE NicOx S.A.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
2. NicOx Opens U.S. Headquarters in New Jersey
3. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
4. Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
5. Accelerated Community Oncology Research Network, Inc. (ACORN), Initiates a Phase 2b Metastatic Breast Cancer Trial in Cooperation With Bayer and Onyx
6. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
7. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
8. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
11. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... NORTH CHICAGO, Ill. , May 26, 2015 ... biopharmaceutical company, announced today that it has completed ... and commercial presence in oncology. Pharmacyclics is a ... (ibrutinib), a first-in-class BTK-inhibitor used to treat hematological ... "The companies, shared expertise, combined with AbbVie,s broad ...
(Date:5/25/2015)... a science-driven healthcare company seeking to solve some of ... that Dame Marjorie Scardino , Chairman of the ... appointed to PureTech,s Board of Directors in the role ... Joi Ito , MIT Media Lab,s Director, has ... PureTech,s outgoing Chairman and co-founder, former Executive Vice President ...
(Date:5/22/2015)... DUBLIN , May 22, 2015  Actavis plc ... of the U.S. Court of Appeals for the Second ... 2014 preliminary injunction requiring the Company to continue distribution ... Logo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO   ... uphold this ruling, we intend to continue our strong ...
(Date:5/22/2015)... -- Baylor Research Institute (BRI) at ... (TGen) in Phoenix, AZ , today ... and treatments for patients with a broad range of cancers. ... new clinical trials and access to technology to drive the ... to bedside across Baylor Scott & White Health,s ...
Breaking Biology Technology:AbbVie Completes Acquisition of Pharmacyclics 2AbbVie Completes Acquisition of Pharmacyclics 3AbbVie Completes Acquisition of Pharmacyclics 4AbbVie Completes Acquisition of Pharmacyclics 5AbbVie Completes Acquisition of Pharmacyclics 6PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 2PureTech Adds Dame Marjorie Scardino to Board of Directors, Names Joi Ito as Chairman of the Board and Expands Management Team 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8Precision Medicine Collaboration to Increase Options for Cancer Patients 2Precision Medicine Collaboration to Increase Options for Cancer Patients 3Precision Medicine Collaboration to Increase Options for Cancer Patients 4
... Jeff Cunningham and Lynn Jordan , ... Massachusetts, USA , Introduction ... is an optional accessory to the Sciclone Advanced Liquid Handler (ALH). This ... wells or columns of 96 and 384 well microplates for purposes of ...
... Geoffrey Grove, Ed Alderman Applied Science and ... Monica Adams, Jason Brennan Development Integration, ... Overview , ... Kit is designed to eliminate the requirement for extended bacterial growth ...
... Rudy Willebrords 1 and Bart Moyson 2 , ... & Development, a division of Janssen Pharmaceutica N.V., Laboratory of Virology, Beerse, Belgium ... Caliper Life Sciences Benelux NV, Teralfene, Belgium , ... purpose of this paper is to report the performance obtained by dispensing 1μL ...
Cached Biology Technology:Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 2Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 3Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 4Precision Testing for the Sciclone Advanced Liquid Handler Z8 Option 5Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 2Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 3Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 4Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 5Scalable Automation of the TempliPhi DNA Sequencing Template Amplification and DYEnamic ET Terminator Sequencing Kits on the Sciclone ALH 3000 696 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 296 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 3
(Date:5/25/2015)... 2015  Australia,s market for wearable technologies is considered ... the advent of several trials and prototypes. The release ... expected to ignite interest in wearables as well as ... . This in turn will spur greater innovation ... partnerships amongst vendors and distributors. Photo ...
(Date:5/22/2015)... According to a new market research report ... by Software (Middleware, Databases), by Hardware (Cameras, Integrated Devices), ... - Global Forecast to 2020", published by MarketsandMarkets, Facial ... to $6.19 Billion by 2020, at a CAGR of ... and   43 Figures spread through 140 Pages and ...
(Date:5/21/2015)... The Sync Project™ , a global collaboration harnessing ... a collaborative partnership with Berklee,s Institute for Creative ... on original research, joint course development and an internship ... Sync Project and BerkleeICE are exploring the launch of ... academic year.  The course will focus ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3
... , , , , , ... AUDIO: Plants capable of producing oils for industrial chemicals and human health are ... Click here for more information. , , , ... , , , , , ...
... de-acetylase (HDAC) inhibitor panobinostat is able to target and ... published in BioMed Central,s open access journal Breast ... Center have shown that panobinostat was able to destroy ... Approximately 15% of breast cancers are found at ...
... Barcelona, 20 May 2012. The Stem Cells and Cancer ... the Vall d,Hebrn Institute of Oncology (VHIO) has identified ... drugs used in clinical trials for colon cancer treatment. ... collaboration with Professor Alberto Muozs laboratory at the Instituto ...
Cached Biology News:Supercharged safflower 2Supercharged safflower 3Supercharged safflower 4Blocking DNA: HDAC inhibitor targets triple negative breast cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 3
Anti-human C3a/C3a des-Arg (neo-epitope), Clone 2991, Monoclonal Antibody...
Phospho-FADD (Ser194) Antibody (Human Specific)...
... polyclonal to FANCM ( Abpromise for ... Synthetic peptide derived from within residues ... (Note: the amino acid sequence is ... ab27787 .) Entrez ...
Rabbit polyclonal to WWOX8 ( Abpromise for all tested applications). entrezGeneID: 51741 SwissProtID: Q9NZC7-8...
Biology Products: